Chronic Pain Clinical Trial
Official title:
A Behavioural Medicine Approach in Physical Therapy for Treatment of Chronic Pain - Evaluation of the Implementation Process and Outcome
Implementation of a behavioral medicine (BM) approach in physical therapy (PT) for patients
with persistent musculoskeletal pain is in accordance with the state of science. Translation
of research into clinical PT practice is challenging and may demand active implementation
strategies.
The aim is to evaluate the implementation of a behavioural medicine approach for patients
with persistent musculoskeletal pain concerning sustainable health benefits and sick-leave,
as well as the cost-effectiveness of the implemented treatment.
Treatment outcomes for patients from two groups of physical therapists in primary care will
be compared. In one group active implementation strategies have been employed, and in the
other (control) passive implementation strategies during a 6-months intervention period.
Patients are recruited during one-year after the implementation period.
The short and long-term effects of the implementation of the BM approach in PT treatment on
patients' sick-leave, activity and participation, and health related quality of life will be
compared to the patients from control condition clinics. The cost-effect and cost-benefit of
an implementation of a behavioral medicine approach in physical therapy is evaluated from the
perspective of the health care organization and society.
The aim is to investigate the short and long-term effects for the implementation of a
behavioral medicine approach in physical therapy on patients' sick-leave, activity and
participation, and health related quality of life, compared to the control condition. Further
the aim is to evaluate the cost-effect and cost-benefit of an active implementation of a
behavioural medicine approach in physical therapy, compared to the passive implementation in
the control condition.
In total 109 primary care patients with musculoskeletal pain ≥ 4 weeks are included
consecutively in the active implementation and passive implementation (control) clinics. The
sample size was based on a priori power analysis on differences in primary outcome between
conditions and expected attrition. Patients from both conditions are included during the
first year after the implementation period.
Data collection has been at onset and end of patients' treatment period, and will be at 6,
12, and 18 months post treatment (in both implementation and control clinics).
Recommended core outcomes regarding body structure, activity and participation are used.
Primary outcomes: Participation in work life defined as days of sick-leave and participation
in everyday life. Secondary outcomes will be patients' ratings of global treatment effects
and pain intensity. Process measures: prognostic psychosocial factors possible to address in
physical therapy such as functional self-efficacy, fear of movement and patient expectations
on treatment effects. Depression, seen as a confounder, will be controlled for. Calculation
of costs will include avoidable cost of the implementation, sunk costs will be ignored.
Direct health care costs, i.e. use of health care services will be identified, measured and
priced to assess costs from a societal perspective. Indirect costs, i.e. production loss due
to sick leave and health care visits will be estimated. Cost-benefit will be calculated from
the perspective of the society. Economic benefits will be measured as the net value of
production gained for society, with an appropriate discount rate. Costs for society will be
calculated on direct health care costs.
Data analyses: Regression models are used to compare patient outcomes between implementation
and control clinics and performed per protocol and on an intention-to-treat-basis. Total
costs, i.e. direct health care costs, direct and indirect non-health care costs and
incremental costs, will be compared between conditions. A ratio between difference in outcome
scores and costs between baseline and 6, 12, and 18 months post treatment will be.
Incremental costs will be calculated per cost-benefit ratio associated with treatments in the
two conditions. Bootstrapping is used for confidence intervals for cost-effectiveness and
cost-benefit ratios.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|